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Abstract: Mesenchymal stem cells (MSCs) are multipotent non-hematopoietic stem cells residing in
many tissues, including the lung. MSCs have long been regarded as a promising tool for cell-based
therapy because of their ability to replace damaged tissue by differentiating into the resident cell and
repopulating the injured area. Their ability to release soluble factors and extracellular vesicles has
emerged as crucial in the resolution of inflammation and injury. There is a growing literature on the
use of MSCs and MSC secretome to hamper inflammation in different lung pathologies, including:
asthma, pneumonia, acute lung injury (ALI), pulmonary hypertension, and chronic obstructive
pulmonary disease (COPD). However, their potential therapeutic role in the context of Cystic Fibrosis
(CF) lung inflammation is still not fully characterized. CF morbidity and mortality are mainly due
to progressive lung dysfunction. Lung inflammation is a chronic and unresolved condition that
triggers progressive tissue damage. Thus, it becomes even more important to develop innovative
immunomodulatory therapies aside from classic anti-inflammatory agents. Here, we address the
main features of CF and the implications in lung inflammation. We then review how MSCs and
MSC secretome participate in attenuating inflammation in pulmonary pathologies, emphasizing the
significant potential of MSCs as new therapeutic approach in CF.
Keywords: inflammation; mesenchymal stem cells; cystic fibrosis; extracellular vesicles;
anti-inflammatory therapy
1. Cystic Fibrosis Lung Inflammation and Current Therapies
Cystic fibrosis (CF) is the most common lethal genetic disease in Caucasian populations. It is a
multisystemic disease characterized by a dysregulated ions flux through the epithelia, and it is caused
by mutations in the gene encoding for cystic fibrosis transmembrane conductance regulator (CFTR)
channel. The multisystemic feature of CF is due to the ubiquitous localization of CFTR, which is
expressed on the apical membrane of epithelial secretory cells. For this reason, CF involves several
organs such as lungs, kidneys, gut, liver, and pancreas. The condition of CF adult patients is further
complicated by several age-related comorbidities such as diabetes, nephropathy, coronary artery
disease, and increased risk of gastrointestinal cancer [1]. However, despite this growing variety of
comorbidities affecting CF patients, morbidity and mortality are mainly due to lung disease. Indeed,
respiratory failure leads to premature death in about 90% of people affected by CF [2].
CF pulmonary manifestations are characterized by progressive damage of pulmonary architecture,
because of persistent infection and chronic inflammation. Deficiency of CFTR functions leads to
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altered ion homeostasis and water flux on pulmonary epithelial surface, resulting in accumulation of
dehydrated, thick and viscous mucus, which tightly adheres to epithelial airways surface and
strongly impairs mucociliary clearance [3,4]. This in turn promotes airways obstruction and
hinders elimination of pathogens. Moreover, pH of CF airways fluid is eight-fold more acidic
than non-CF [5], further contributing to inappropriate microbial clearance because of inactivation of
mucus antimicrobial peptides [6]. Finally, recurrent and unresolved microbial colonization promotes
a chronic state of infection. Indeed, Staphylococcus aureus and Haemophilus influenza colonize CF
lungs very early in patients’ life [7], while during adolescence and adulthood, Pseudomonas aeruginosa
and other bacterial/non-bacterial microorganisms, worsen pulmonary conditions [7]. Pathogens
colonization induces an intense inflammatory response, which is ineffective in eradicating infections
and perpetuates over time. The unresolved chronic inflammation becomes harmful and finally
compromises respiratory function. Though CF inflammatory condition is characterized by a massive
neutrophil influx, driven by chemotactic signals, these neutrophils fail in resolving infection, accumulate
in the pulmonary tissue [8,9] and secrete pro-oxidants mediators and proteases that exacerbate the
inflammatory milieu. High levels of neutrophil elastase (NE) in CF sputum correlate with lung disease
progression [10]. NE affects the airways remodeling, impairs mucociliary clearance, and activates matrix
metalloproteinases [11,12], thus contributing to destroy the architecture of airways epithelium [13].
CF patients display altered mechanisms of phagocytosis to eliminate dead neutrophils, which further
fuel chronic inflammation by accumulating and releasing great amounts of intracellular material.
CF airways are characterized by an imbalance between pro- and anti-inflammatory mediators [14–16].
Bronchoalveolar lavage (BAL) of infants younger than 3 years old, revealed high concentrations
of IL-8 even in the absence of any detectable infection [17,18], suggesting that inflammation is an
intrinsic feature of CF airways, independent from microbial colonization. Moreover, it has been
demonstrated that CF patients have an impaired capacity to biosynthesize specialized pro-resolving
lipid mediators (SPMs), like lipoxins, maresins, protectins, and resolvins, because of the altered
metabolism of arachidonic acid and docosahexaenoic acid [16,19,20]. This inefficient production
of bioactive lipids significantly contributes to the defective resolution of inflammation in CF since
SPMs restore functions that are altered in CF airway such as stimulation of macrophage bactericidal
activity [21,22], stimulation of epithelial chloride secretion and airway surface liquid layer height
increase [23,24], and enhancement of epithelial cohesion and repair [25,26].
Because of the significant impact of the lung dysfunction affecting CF patient, a great deal of
effort has been put in identifying various therapeutic strategies toward lung manifestations. Almost
2000 mutations in the CFTR gene have been identified allowing the development of novel therapies
targeting specific molecular basic defects (for a comprehensive review please refer to Pranke et al.
2019 [27]). Some of these mutation specific strategies aim to restore mRNA levels, correct CFTR
folding and trafficking to the apical plasma membrane (correctors) or increase the CFTR channel
function (potentiators). However, molecules targeting basic defects of CFTR protein are specific
and address only patients carrying a specific mutation/class of mutation. Other therapies that are
in preclinical development are not mutation specific and include gene therapy to edit the genome
and stem cell therapy to repair the airway tissue. Indeed, CF being a monogenic disease is an ideal
candidate for gene therapy. Genetic therapies using viral and non-viral vectors, the use of CRISPR/Cas9
approach, antisense oligonucleotides and RNA- mediated therapy are promising tools for CF treatment
that are been tested in preclinical studies [27]. With the discovery of the induced pluripotent stem
cells (iPSCs), stem cells therapy in combination with CRISPR/Cas9 technology theoretically allow to
re-graft the lung niches and repopulate the respiratory cells. However, important limitations have
hindered CFTR gene therapy such as the expensiveness, the difficult delivery to the lungs and the
necessity of repeated administration. Moreover, time and labor efforts together with the complication
to obtain fully differentiated lung-specific cell subsets limit the efficacy of stem cell-based therapy.
Lung transplantation is the only therapeutic life-saving option for patients with end-stage lung disease.
Although it has evolved over the last decades, the median survival after surgery for CF patients is
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9.5 years as reported by the International Society for Heart and Lung Transplantation [28]. Lung
transplantation is a high-risk procedure and it implies transplant-associated complications and graft
dysfunctions [29,30]. Therefore, the benefit/risk rate of this therapeutic approach is still controversial.
While no cures for CF are known, currently available therapies target symptoms. Given the key
role of chronic inflammation in worsening CF lung pathological condition, it is important to consider
pulmonary inflammation as a therapeutic target. Indeed, counteracting inflammation could slow
down pulmonary decline and preserve respiratory capacity, improving the quality of patients’ life.
Several anti-inflammatory strategies have been investigated in the last 20 years though few of them
have been translated into clinical application (see Table 1). The use of anti-inflammatory treatment, by
aerosol or orally, is limited by the undesired side effects such as intolerance to glucose, diabetes, growth
impairment, cataracts, gastrointestinal toxicity [31,32]. Therefore, the need to develop innovative
immunomodulatory therapies aside from the classic anti-inflammatory agents is compelling. Though
in its early beginning, accumulating evidences support the hypothesis that mesenchymal stem cells
(MSCs) treatment represents a novel strategy to be investigated in CF.
Table 1. Overview of the main cystic fibrosis anti-inflammatory therapies in preclinical or clinical phase.
Compound Status References
Systemic corticosteroids Clinical trials [33–36]
Inhaled corticosteroids Clinical trials [37]
Ibuprofen In therapy [31]
Acebilustat Clinical trials NCT02443688
Azithromycin In therapy [38–41]
α1-antitrypsin Clinical trials [42,43]
Glutathione Clinical trials [44–46]
N-acetylcysteine Clinical trials [47–50]
Thiocyanate Preclinical studies [51]
SB-656933 Clinical trials [52]
Anakinra Preclinical studies [53–55]
IL-10 Preclinical studies [56,57]
Dornase alfa In therapy [36]
DHA Clinical trials [58–60]
LAU-7b Clinical trials NCT03265288
Sildenafil Clinical trials [61]
Vardenafil Preclinical studies [62]
Myriocin Preclinical studies [63,64]
Amitriptyline Clinical trials [65–67]
Miglustat Preclinical studies [68]
Ajulemic acid Clinical trials [69], NCT02465450
KB001-A Clinical trials [70]
Mesenchymal stem cells Preclinical studies [71–73]
Mesenchymal stem cells-derived EVs Preclinical studies [74]
2. Mesenchymal Stem Cells: Principal Characteristics and Regenerative Properties
MSCs were originally discovered in bone marrow by Friedenstein and colleagues in 1968 [75].
Successively, MSCs have been isolated from a variety of tissues, such as umbilical cord blood, Wharton’s
jelly, placental, and adipose tissues [76–78]. Likewise, MSCs have been identified in the lung tissue
as important components of the parenchymal progenitor cell niche, orchestrating organ homeostasis,
and injury repair [79]. MSCs represent a subpopulation of stem cells in the context of mesenchymal
stromal cells, according to the current criteria of isolation that produce heterogeneous, non-clonal
cultures of stromal cells containing stem cells with different multi potential properties, committed
progenitors, and differentiated cells. Stromal cultures obtained from various tissues that contain a
subpopulation of stem cells are used for therapeutic purposes, since they might be effective in the
treatment of several diseases [80]. In 2006, the Mesenchymal and Tissue Stem Cell Committee of the
Cells 2020, 9, 20 4 of 17
International Society for Cellular Therapy, recommended minimal criteria for their characterization [81].
Because of the low expression of MHC class I and no expression of MHC class II, MSCs are considered
immunopriviledged cells, able to avoid immunosurveillance [82].
Homing and migration are other peculiar characteristics of MSCs. Many studies have demonstrated
that when systemically administered, MSCs are recruited to the injured sites to exert their therapeutic
effects. Once engrafted, they replace damaged tissue through differentiation into the resident cells and
repopulation of injured area [83–85]. For these reasons, they have been regarded as an encouraging
tool for regenerative medicine. Concerning pulmonary tissues, increasing evidences support MSCs
regenerative properties. Indeed, they were able to engraft and to differentiate into lung epithelial
cells under experimental conditions such as irradiation, bleomycin, or LPS-induced injury [86–88].
A systematic review of seventeen studies on rodents models of bleomycin-induced pulmonary fibrosis,
describes the beneficial effects of MSCs, mostly derived from bone marrow, in improving alveolar
injury and in decreasing lung fibrosis and collagen content [86]. Aged Balb/C mice infected with highly
pathogenic H5N1 and H7N9 influenza viruses, show impaired alveolar fluid clearance and protein
permeability. The pathological phenotype was reduced by injected intravenous administration of
human MSCs derived from bone marrow [89]. In a mouse model of acute respiratory distress syndrome
(ARDS) induced by LPS, Gupta N. and colleagues demonstrated that systemic administration of MSCs
significantly improved alveolar injury [90]. MSCs-treated mice showed attenuated fibrosis and reduced
collagen accumulation consequent to irradiation-induced lung injury [91].
However, a growing body of evidence suggests that MSCs ability to repair and improve injured
tissues function do not necessarily require significant engraftment or differentiation rate. The low
survival rate of the transplanted MSCs in the recipient tissue may be affected by culture conditions
or by cell death caused by lack of proper interconnections, thus representing a great limitation to
their use [92]. In fact, numerous preclinical studies have shown that the engraftment rate is very low,
near 5% [85,93]. This supports the hypothesis that the regenerative ability may be mediated by their
secretome. Indeed, MSCs paracrine effects are extensively studied, and it is widely accepted that their
secretome is majorly responsible for the intercellular crosstalk between MSCs and targeted cells [94–96].
Bioactive factors secreted by MSCs are known to mediate some of the functions of MSCs, such as the
immunomodulatory, anti-inflammatory, anti-oxidant, and anti-apoptotic activity. They also contribute
to tissue regeneration, angiogenesis, and clearance of microorganisms. Other than the soluble factors,
MSCs also secrete different types of extracellular vesicles (EVs) accounting for their secretome and
supporting all their therapeutic effects [97–101].
Despite the abovementioned regenerative properties of MSCs, this review focuses on the
immunomodulatory and anti-inflammatory effects of MSCs on lung inflammatory pathologies, with a
peculiar attention toward CF, that is still a poorly investigated field.
3. Mesenchymal Stem Cells in Lung Inflammation
MSCs can modulate the inflammatory response during pulmonary inflammation restoring the
balance between the cytokine network and other humoral or cellular effectors of the immune system.
Several preclinical studies demonstrated that the administration of MSCs stimulates the reduction
of pro-inflammatory cytokines and the increase of anti-inflammatory markers and cytokines in lung
tissues [102–105]. Moreover, MSCs treatment promoted neutrophil-mediated phagocytosis in vitro
and in vivo and thus bacterial clearance [106] as well as specialized pro-resolving lipid mediators
release, particularly D-series resolvins [107] in a model of sepsis. In Escherichia coli-induced pneumonia,
the intratracheal MSCs treatment was as effective as intravenous therapy decreasing the infiltration of
neutrophils, reducing lung bacterial load and suppressing inflammation [108]. Pedrazza and colleagues
found that MSCs reduced inflammation, oxidative damage, and consequently decreased the release
of neutrophil extracellular traps in a LPS-induced acute lung injury (ALI) model [109]. They also
demonstrated that treatment with MSCs was able to reduce COX-2 and NF-κB and to inhibit the
MAPK pathway activation, modulating the inflammatory response during sepsis [110]. MSCs can
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promote macrophage differentiation to M2 phenotype contributing to the resolution of inflammation,
and conversely, to M1 phenotype leading to augmented phagocytic activity [102,111]. Recent studies
have demonstrated that MSCs can also transfer functional mitochondria to the damaged cells reducing
oxidative stress in lung injury [112,113]. Keeping in view that oxidative stress-induced mitochondrial
dysfunction can contribute to inflammation, transfer of mitochondria could be consider another
anti-inflammatory effect of MSCs. Indeed, mitochondria delivered from iPSC-MSCs to airway smooth
muscle cells alleviate airway inflammation and hyper responsiveness in COPD models of human
lung cells and mouse lungs [112]. Moreover, mitochondrial transfer from iPSC-MSCs to epithelial
cells through tunneling nanotubes attenuated the mitochondrial dysfunction and ameliorated asthma
inflammation in mice [113].
The increasing number of MSCs-based clinical trials in lung pathologies, either complete or ongoing,
supports the feasibility of this therapeutic approach. Indeed, MSCs are easy to isolate and expand in
culture, they have inherent low immunogenicity and limited risk of tumorigenicity and are easy to
be administered. According to the US National Institutes of Health (http://www.clinicaltrials.gov/)
until December 2019, almost 10% of MSCs-based clinical trials in lung diseases were performed using
autologous MSCs. In 50% of allogeneic MSCs-based clinical trials, bone marrow MSCs from healthy
donors were administered to patients, whereas almost 40% of the remaining trials were carried out with
perinatal MSCs. Among perinatal sources cord blood was the most tested, but also umbilical cord- and
placenta-derived MSCs were studied. MSCs were administered by intravenous infusion (as shown by
half of clinical trials), single intratracheal administration or via bronchoscopy among others. The dosage
of administration largely varied from 1–5 × 106 to 10–20 × 106 cells/kg or 100–200 × 106 cells/infusion.
However, MSCs-based therapy faces significant hurdles in its translation to clinic as elegantly
described by Galipeau J. [114]. The long-term benefits of MSCs are not currently clear and the final
outcome is highly dependent on patient inter-variability [115]. Data arising out of MSCs-based clinical
trials demonstrate the variability of the use of this therapy in terms of MSCs source, route, timing, and
dosage of administration. As very recently reviewed by Zanoni M. et al. [87], the lack of consensus on
these parameters (route, timing and dosage) together with the paucity of standardized methods for
MSCs harvesting, request further studies in order to include MSCs therapy in the clinical practice in the
near future. Moreover, donor variance, senescence, cryopreservation, and sources are among the main
variables that can affect cellular therapies based on MSCs [116,117]. Specifically, the MSCs source is an
important point to be addressed since it may result in different effects in respiratory diseases. In a rat
model of ARDS, Silva J.D. and colleagues observed that both bone marrow- and adipose tissue-derived
MSCs yielded greater beneficial effects in term of reduced expression of pro-inflammatory cytokines
than lung- derived MSCs [118]. On the other hand, the potential risk of unpredictable cell growth and
differentiation of MSCs-based therapy is still a major concern [119].
The low rates of engraftment suggest that the therapeutic benefits of MSCs mostly derive from
the paracrine effects of their secretome. Thus, cell-free approach using the MSCs secretome arises
as a powerful tool against lung inflammation with the same positive effects of MSCs, but with less
unwanted secondary effects as recently reviewed [120–122].
4. Mesenchymal Stem Cells-Derived Conditioned Medium in Lung Inflammation
The potential of MSCs-conditioned media (CM) to mimic the anti-inflammatory mechanisms of
the parental MSC has been proved in several studies using different animal models of lung injury.
In acute and chronic asthma, intranasal instillation of bone marrow MSCs-CM reduced lung levels of
the inflammatory cytokines IL-4 and IL-13 and increased levels of IL-10. MSCs-CM prevented airway
hyper responsiveness, smooth muscle thickening, and peribronchial inflammation via adiponectin,
an anti-inflammatory adipokine found in the CM [123]. Pretreatment with MSCs-CM protected against
lung ischemia-reperfusion (IR) injury in a rat model with a significant reduction in proinflammatory
cytokines, a decrease in infiltrating inflammatory cells, and an increase in M2-like macrophages
and regulatory T cells [124]. Shen and colleagues studied the protective effects of bone marrow
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MSCs-CM on bleomycin induced lung injury and fibrosis, both in vitro (A549 alveolar epithelial
cells) and in vivo (rat model). Following MSCs-CM treatment, A549 cells were significantly protected
from bleomycin-induced apoptosis while bleomycin-challenged rat lungs exhibited a reduction in
inflammation, fibrotic scores, collagen deposition, and cell apoptosis [125]. In a rat model of COPD,
the administration of MSCs-CM attenuated the cigarette smoke-induced emphysema and increased
the number of small pulmonary vessels as well as the MSCs [126].
A main limitation in the use of MSCs-CM is the relatively rapid degradation of bioactive molecules
in extracellular medium [119]. Moreover, the preconditioning process, the optimal dose, timing and
route of administration lack fully standardized protocols. Lately, EVs have attracted the scientific
community’s attention for their role in transporting both bioactive molecules, thus preventing them
from hydrolysis, and DNA, thus avoiding mutations [127]. Given their potential, EVs arise as a good
candidate for cell-free therapy in regenerative medicine.
5. Mesenchymal Stem Cells-Derived EVs in Lung Inflammation
EVs are diverse populations of small, lipid-enclosed, cell-derived particles released by almost all
cellular types to promote cell-cell communication [128–130]. They function as shuttle vehicles toward
target cells for their content, but also for soluble factors in the microenvironment that can bind to their
membranes [131,132]. MSCs release diverse classes of EVs, including exosomes, microvesicles and
apoptotic bodies. Several parameters have been used to classify EVs such as the cellular origin, secretory
mechanism, size, and surface markers. Nevertheless, most of these parameters are not exclusive to
any specific type of EVs [133]. Recent evidences suggest that EVs secreted from MSCs may release
bio-active protein, lipid, and nucleic acid cargo to promote functional changes in the recipient injured
cells [134,135]. MSCs-derived EVs have been shown to suppress pro-inflammatory processes and
reduce pulmonary fibrosis in a variety of experimental models of inflammatory lung diseases, including
asthma, pulmonary artery hypertension, ALI, ARDS, and pneumonia by transferring their components.
In a murine model of hypoxia-induced pulmonary hypertension, the intravenous administration
of MSCs-derived exosomes inhibited STAT3 signalling and restored the levels of both the miR-17 and
the miR-204 superfamily, resulting in the inhibition of vascular remodelling and hypoxic pulmonary
hypertension [98]. Zhu and colleagues demonstrated that human bone marrow MSCs-derived
EVs were effective in reducing lung inflammation in Escherichia coli endotoxin-induced ALI in
C57BL/6 mice. The intratracheal delivery of EVs, attenuated the pulmonary edema, the lung protein
permeability, the influx of neutrophils, and the expression of macrophage inflammatory protein-2 in
the BAL fluid [99]. Results from the same group demonstrated that EVs derived from human MSCs
limited the influx of inflammatory cells, cytokines, and bacteria in a murine model of Escherichia coli
pneumonia. Besides, they found that EVs increased monocyte phagocytosis of bacteria while
decreasing inflammatory cytokine secretion in injured alveolar epithelial type 2 cells [136]. Interestingly,
EVs isolated from human MSCs were more efficient than those from mouse MSCs in a preclinical
model of asthma. The systemic administration of EVs from both sources of MSCs ameliorated the
Aspergillus hyphal extract-induced increases in airway hyper reactivity and lung inflammation in
immunocompetent C57Bl/6 mice [137]. In a model of lung fibrosis, the intravenous treatment with
isolated human MSCs-derived exosomes, significantly reduced the extent of monocyte infiltration
and expression of inflammatory and pro-fibrotic genes in the lung [127]. Alveolar macrophages
pre-treated with MSCs-derived EVs reduced the inflammation and lung injury in LPS-injured mice.
This effect was induced by EVs-mediated mitochondrial transfer as reported by Morrison et al. [138].
The anti-inflammatory and immunomodulatory activity of MSCs-derived EVs was found to attenuate
lung IR injury in mice. A significant downregulation of proinflammatory cytokines (IL-17, TNF-α,
CXCL1, and HMGB1) together with an increase of keratinocyte growth factor, prostaglandin E2,
and IL-10 occurred in the BAL fluid from EVs-treated mice [139]. Human MSCs-derived EVs have
also been tested in hyperoxic-induced lung injury models using newborn mice [140] and newborn
Sprague-Dawley rats [141]. Willis and colleagues found a macrophage phenotype modulation toward
Cells 2020, 9, 20 7 of 17
an anti-inflammatory M2-like state after the MSCs-exosome treatment, resulting in the amelioration
of lung function, pulmonary fibrosis, vascular remodelling, and pulmonary hypertension [140].
Accordingly, in the neonatal rat model, MSCs-derived EVs were as effective as parental MSCs to
confer a VEGF mediated-protection against activated macrophages, proinflammatory cytokines, and
augmented cell death [141]. Recently, it was demonstrated that MSCs-EVs have anti-influenza and
anti-inflammatory properties in a pig model of influenza virus because of RNAs transfer to epithelial
cells. EVs inhibited the hemagglutination activity of avian, swine, and human influenza viruses
and inhibited influenza virus replication and virus-induced apoptosis in lung epithelial cells [142].
Several evidences indicated that MSCs-derived EVs can carry miRNAs, which have anti-apoptotic
properties and can contribute to contrast pulmonary inflammation [143–145]. Indeed, in a murine
model of sepsis, MSCs promote macrophage polarization to the M2 phenotype not only in vitro but
also in lung and liver tissues. These immunomodulatory properties were mediated by the release
of the exosomal miR-146a [143]. Apoptosis of epithelial and endothelial cells increases blood vessel
wall permeability, which allows neutrophil infiltration and aggravates the pulmonary edema and
inflammation. Hence, the delivery of anti-apoptotic miRNAs by MSCs could be a promising approach
to ameliorate inflammation. Finally, anti-apoptotic miRNAs miR-30b-3p and miR-21-5p carried by
MSCs-derived exosomes conferred protection against ALI and decreased the apoptosis of alveolar
epithelial and endothelial cells, respectively [144,145].
One important therapeutic advantage of EVs, is the encapsulation and protection of their cargo
from unfavorable conditions, such as changes in pH or degradation in vivo. In fact, MSCs-EVs can be
used to deliver to target organs specific compounds which are overexpressed by the MSCs themselves
or which can be loaded directly into the EVs. Moreover, they easily enter the systemic circulation
and maintain long lasting high concentrations, while the concentration of transfused MSCs drops
rapidly [146]. EVs are not self-replicating, thus reducing the risk of tumor formation and can be stored
for several months at −20 ◦C or −80 ◦C, without cryopreservatives, remaining biologically active.
Nevertheless, also the use of EVs in clinics has to overcome several limitations such as quantification,
scaling up EVs production, delivery route, and effective doses [147]. The heterogeneity of EVs
population is another issue that should be carefully addressed together with the great variability of the
bioactive compounds content which can be highly modulated by cell culture conditions and stimuli
that trigger their release. Despite the extensive use of MSCs and their secretome in different scenarios
of lung inflammation, as summarized in Figure 1, their potential has been poorly studied in the context
of CF lung inflammation.
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Figure 1. Anti-inflammatory effects of mesenchymal stem cells (MSCs) and secretome on lung
inflammation. The scheme represents the main inflammatory mediators modulated by MSCs and
secreto e in lung diseases. The green color used for the boxes and the arrows indicate anti-inflammatory
mediators and functions induced by MSCs and/or MSCs-derived conditioned medium (CM) or
extracellular vesicles (EVs). The red color used for the boxes and the arrows indicate pro-i fla matory
mediators and functions counteracted by MSCs and/or MSCs-derived CM or EVs. CXCL-1/CXCL-10:
chemokine (C-X-C motif) ligand-1/ligand-10; COX-2: cyclooxygenase 2; IFN-γ: gamma interferon; LL37:
antimicrobial peptide; MCP-1: monocyte chemoattractant protein 1; MIP- : macrophage inflammatory
protein 2; NF-κB: nuclear factor κB; PGE2: prostaglandin 2; SPMs: specialized pro-resolving lipid
ediators; TNF-α: tumor necrosis factor alpha.
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6. Mesenchymal Stem Cells as Anti-Inflammatory Therapy in Cystic Fibrosis
Bonfield’s group was the first to approach the study of MSCs as anti-inflammatory therapy in
CF. In 2013, they reported for the first time that in an in vivo model mimicking CF lung infection
and inflammation, human MSCs treatment attenuated pro-inflammatory cytokines levels, weight
loss, clinical score, and lung pathology associated with chronic infection with Pseudomonas aeruginosa.
Their results suggested that the mechanisms supporting the anti-inflammatory and anti-microbial
effects involved soluble factors of the human MSCs media, like the cathelicidin LL-37 [71]. In another
study using Pseudomonas aeruginosa and Staphylococcus aureus, they strengthened that the antimicrobial
efficacy of human MSCs is due to the release of the antimicrobial peptide LL-37 which slows the
rate of bacterial growth [72]. They also demonstrated that the source of the human MSCs (bone
marrow or adipose tissue), growth conditions, concentration and time course could impact the overall
antimicrobial efficiency. Of interest, in in vitro antimicrobial assays, MSCs with dysfunctional CFTR
channel were not as efficient in handling infection as MSCs with fully active CFTR channel, suggesting
the same scenario for CF patient’s MSCs as compared to healthy individual’s MSCs [72]. Lately, they
investigated the anti-inflammatory properties of human MSCs in both Gram negative (Pseudomonas
aeruginosa) and Gram positive (Staphylococcus aureus) CF murine models. They found that MSCs have
the ability of selectively recruiting more lymphocytes than monocytes or neutrophils and of modulating
the immune response balance enhancing the expression of anti-inflammatory chemokines IL-6 and
CCL2, while decreasing IL-8 expression. They confirmed that inadequate CFTR activity alters the
ability of the MSCs to respond to LPS and Gram negative bacteria and it is associated with a deficiency
of the anti-inflammatory transcriptional regulator PPARγ, further contributing to inflammation. On the
other hand, healthy MSCs were able to reestablish PPARγ expression in CFTR-deficient macrophages
as a potential mechanism implicated in the MSCs anti-inflammatory effectiveness in CF [73]. In
support of these findings, very recent data from our group demonstrated that human lung MSCs
and MSCs-derived EVs could be immunologically altered in CF [148]. In a model of CF-MSCs, CFTR
dysfunction associates with an enhanced sphingolipid metabolism leading to the release of EVs that
export the excess of pro-inflammatory ceramides to the recipient cells, thus contributing to maintain
the unresolved inflammatory status of CF [148].
We also explored the anti-inflammatory effects of EVs, released from human lung MSCs, in CF
bronchial epithelial cell models. We found that MSCs-derived EVs down-regulated the transcription and
expression of pro-inflammatory cytokines such as IL-1β, IL-8, IL-6 under TNFα-stimulated conditions
and partially impaired the nuclear translocation of NF-κB. EVs treatment enhanced the antioxidant
defensive response of the CF cells by means of up-regulating heme oxygenase-1 (HO-1) transcription.
Noteworthy, we found that MSCs-derived EVs treatment partially restored PPARγ signaling in CF
deficient cells, accordingly to the results of Bonfield’s group. Hence, we proposed the modulation of
PPARγ axis and its down-stream effectors (NF-κB and HO-1) as a possible mechanism supporting the
anti-inflammatory effects of MSCs-derived EVs in CF [74]. Data by our and Bonfield’s group suggest
that the lung MSCs compartment could be immunologically impaired in CF, thus contributing to
maintain the unresolved pulmonary inflammation. This prompt us to hypothesize that allogeneic
MSCs or MSCs-derived EVs administration could represent a novel anti-inflammatory strategy to
be investigated. Despite the relatively low abundance of preclinical research concerning the use of
MSCs in CF, currently there are two ongoing phase I clinical trials (NCT02866721 and NCT03058068).
These are aimed to evaluate the safety, tolerability, and efficacy of the administration of allogeneic
MSCs in CF patients and will provide the rationale for new MSCs-related therapeutic approaches.
7. Conclusions
While great progresses have been achieved in the study of MSCs, many challenges remain
open before their use can be translated in CF clinical therapy. The very high patient inter-variability
together with the not completely clear long-term benefits of MSCs may represent a limitation to
their use. The preclinical studies reviewed here emphasize the significant potential of MSCs for
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treating pulmonary inflammatory pathologies, including CF. Continuous efforts should be dedicated
to optimize MSCs preparation and administration, dosage, route of administration and to enhance the
survival rate of the transplanted MSCs in the recipient tissue.
As it concerns the use of EVs, it becomes necessary to deeply characterize EVs’ population and their
bioactive modulators profile, and to better elucidate possible mechanisms underlying their activity.
Moreover, the consolidated anti-inflammatory potential exhibited toward multiple inflammatory
pulmonary conditions and the very recent results in CF models, encourage to go further with the
research in this innovative field.
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